Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTLF FitLife Brands	$13.32 -2.3%	$14.27	$9.83 ▼ $17.75	$125.09M	0.81	16,851 shs	8,451 shs
KRRO Korro Bio	$12.35 -0.9%	$14.60	$10.29 ▼ $98.00	$115.97M	2.45	110,446 shs	131,615 shs
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$129.80M	0.52	530,292 shs	756,031 shs
PLUR Pluri	$3.96 -8.1%	$4.70	$3.33 ▼ $7.13	$31.03M	0.77	16,743 shs	140,426 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTLF FitLife Brands	0.00%	-4.86%	-4.86%	-1.19%	-3.79%
KRRO Korro Bio	0.00%	-8.79%	-16.61%	-48.02%	-63.25%
LXEO Lexeo Therapeutics	0.00%	-0.76%	+26.95%	+44.28%	-75.00%
PLUR Pluri	0.00%	-9.79%	-12.00%	-10.00%	-29.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FTLF FitLife Brands	4.1665 of 5 stars	3.7	3.0	1.9	3.3	3.1
KRRO Korro Bio	1.9125 of 5 stars	3.6	3.0	1.1	0.0	0.6
LXEO Lexeo Therapeutics	2.7914 of 5 stars	4.5	2.0	0.0	2.5	0.6
PLUR Pluri	1.5734 of 5 stars	3.5	3.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTLF FitLife Brands	3.33	Buy	$20.50	53.90% Upside
KRRO Korro Bio	3.29	Buy	$102.43	729.38% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
PLUR Pluri	3.00	Buy	$12.00	203.03% Upside

Current Analyst Ratings Breakdown

Latest PLUR, LXEO, KRRO, and FTLF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
6/2/2025	PLUR Pluri	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/16/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTLF FitLife Brands	$64.47M	1.94	$1.01 per share	13.15	$3.93 per share	3.39
KRRO Korro Bio	$2.27M	51.09	N/A	N/A	$17.12 per share	0.72
LXEO Lexeo Therapeutics	$650K	199.71	N/A	N/A	$3.53 per share	1.11
PLUR Pluri	$330K	93.96	N/A	N/A	$1.00 per share	3.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTLF FitLife Brands	$8.98M	$0.84	15.86	12.11	N/A	13.85%	25.59%	15.26%	N/A
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	N/A

Latest PLUR, LXEO, KRRO, and FTLF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/13/2025	Q3 2025	PLUR Pluri	N/A	-$0.94	N/A	-$0.94	N/A	$0.43 million
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTLF FitLife Brands	0.19	1.64	0.72
KRRO Korro Bio	N/A	9.41	9.41
LXEO Lexeo Therapeutics	0.01	3.42	3.42
PLUR Pluri	51.65	4.81	4.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTLF FitLife Brands	2.32%
KRRO Korro Bio	13.18%
LXEO Lexeo Therapeutics	60.67%
PLUR Pluri	16.59%

Insider Ownership

Company	Insider Ownership
FTLF FitLife Brands	61.30%
KRRO Korro Bio	4.60%
LXEO Lexeo Therapeutics	5.30%
PLUR Pluri	25.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
PLUR Pluri	150	7.83 million	5.80 million	Optionable

PLUR, LXEO, KRRO, and FTLF Headlines

Recent News About These Companies

Alliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy Recommendation

June 2, 2025 | msn.com

Pluri Inc. reschedules 2025 annual meeting

May 27, 2025 | investing.com

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

May 27, 2025 | prnewswire.com

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans

May 19, 2025 | msn.com

Pluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

May 16, 2025 | finanznachrichten.de

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

May 16, 2025 | tmcnet.com

Pluri: Fiscal Q3 Earnings Snapshot

May 13, 2025 | timesunion.com

Pluri Inc. acquires majority stake in Kokomodo Ltd.

April 30, 2025 | uk.investing.com

Pluri acquires 71% stake in Kokomodo

April 29, 2025 | foodbusinessnews.net

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

April 28, 2025 | globenewswire.com

Pluri Inc. enters agreement, issues pre-funded warrants

April 27, 2025 | investing.com

Ukraine gains access to Israeli anti-radiation drug amid nuclear threats

April 21, 2025 | msn.com

Ukraine prepares for nuclear emergency - Israel to help save thousands

April 21, 2025 | msn.com

In case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatment

April 20, 2025 | msn.com

Innovative Treatment Aims to Protect Ukrainians from Nuclear Radiation Threat

April 17, 2025 | themunicheye.com

Pluri announces USPTO issued patent covering its immune cell expansion tech

April 12, 2025 | markets.businessinsider.com

Pluri’s immune cell expansion technologies gain patents

April 11, 2025 | finance.yahoo.com

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

April 10, 2025 | finance.yahoo.com

Using cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech?

March 14, 2025 | msn.com

Pluri announces exclusive collaboration agreement with Hemafund

March 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, LXEO, KRRO, and FTLF Company Descriptions

FitLife Brands NASDAQ:FTLF

$13.32 -0.31 (-2.27%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.37 +0.05 (+0.38%)

As of 06/20/2025 07:03 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Korro Bio NASDAQ:KRRO

$12.35 -0.11 (-0.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.37 +0.02 (+0.16%)

As of 06/20/2025 04:09 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 06/20/2025 06:43 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Pluri NASDAQ:PLUR

$3.96 -0.35 (-8.12%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$4.02 +0.06 (+1.52%)

As of 06/20/2025 04:38 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time